Cerenome reports no dose-limiting toxicities in first 10 patients on repeat intraventricular REYOBIQ
Interim Phase 1 ReSPECT-LM data suggest repeated intraventricular dosing of rhenium Re186 obisbemeda is feasible in leptomeningeal metastases from solid tumours; the drug remains investigational.
Cerenome announced on 16 November 2026 interim results from its Phase 1 ReSPECT-LM trial of repeated intraventricular REYOBIQ (rhenium Re186 obisbemeda) in patients with leptomeningeal metastases from solid tumours. The data were presented as a poster at the Society for Neuro-Oncology (SNO) annual meeting on 13 November.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Cerenome, Inc. ↗
Article written by VigiEye from the official source (Cerenome, Inc.). Claims are the company's own. AI-assisted; check the source before acting.